藏药十二味翼首散通过抑制NF-κB介导的NLRP3炎症小体/细胞焦亡通路改善甲流病毒感染的小鼠急性肺损伤

    Tibetan Medicine Shierwei Yishou San Alleviates Acute Lung Injury in Influenza A Cirus-infected Mice by Inhibiting the NF-κB-mediated NLRP3 Inflammasome/Pyroptosis Pathway

    • 摘要:
      目的  探讨十二味翼首散对甲型H1N1流感病毒诱导急性肺损伤的保护作用,并阐明其潜在的分子机制。
      方法 将108只BALB/c小鼠随机分为6组,分别为溶媒组、模型组、十二味翼首散低、中、高剂量组及阳性药组,每组18只。除溶媒组外,其余各组均采用H1N1-PR8毒株滴鼻感染,构建甲型H1N1流感病毒感染致小鼠急性肺损伤模型;各给药组分别灌胃给予十二味翼首散(低、中、高剂量)以及阳性药物磷酸奥司他韦。通过观测小鼠生存率、体质量变化、肺组织病毒载量/滴度、炎症反应和病理损伤程度,评价十二味翼首散对甲型H1N1流感病毒感染急性肺损伤的药效作用。利用网络药理学预测十二味翼首散改善甲型H1N1流感病毒诱导急性肺损伤的潜在作用机制,并利用上述体内药效实验的肺组织标本,验证相关通路机制关键基因与蛋白表达水平。
      结果 药效实验结果显示,十二味翼首散可对H1N1感染小鼠的生存率与体质量发挥一定保护效应,可明显抑制肺组织内的病毒复制,减轻小鼠体内的炎症反应和病理损伤。网络药理学预测结果显示,十二味翼首散中的4味核心药材干预甲型H1N1流感病毒感染及肺损伤的潜在作用机制,可能与NOD样受体信号通路中的NLRP3炎症小体介导的细胞焦亡通路密切相关。机制验证表明,十二味翼首散能够抑制NF-κB活化,下调NLRP3、Caspase-1、GSDMD mRNA及蛋白的表达水平,同时抑制Caspase-1活化及其介导的GSDMD蛋白剪切过程。
      结论 十二味翼首散可通过抑制NF-κB介导的NLRP3炎症小体/细胞焦亡通路,改善甲型H1N1流感病毒诱导的小鼠急性肺损伤。

       

      Abstract:
      OBJECTIVE To investigate the protective effect of Shierwei Yishou San(SYS) against acute lung injury induced by influenza A(H1N1) virus, and to elucidate its potential molecular mechanism.
      METHODS A total of 108 BALB/c mice were randomly divided into 6 groups, namely vehicle group, model group, low, medium, high dose SYS group, and positive group, with 18 mice in each group. Except for the vehicle group, mice in the other groups were infected intranasally with the H1N1-PR8 strain to establish the mouse model of acute lung injury induced by H1N1 virus infection. Mice in each administration group were intragastrically given low, medium and high doses of SYS as well as the positive drug oseltamivir phosphate. The pharmacodynamic efficacy of SYS against acute lung injury induced by H1N1 virus infection was evaluated by observing the survival rate, body weight changes, lung tissue viral load/titer, inflammatory response, and the degree of pathological damage. Network pharmacology was used to predict the potential mechanisms by which SYS alleviates H1N1 virus-induced lung injury, and lung tissue samples obtained from the above in vivo pharmacodynamic experiments were used to verify the expression levels of key genes and proteins in the relevant pathway.
      RESULTS Pharmacodynamic experiments results revealed that SYS had a certain protective effect on the survival rate and body weight of H1N1 virus-infected mice, significantly inhibited viral replication in lung tissues, and alleviated inflammatory responses and pathological damage in mice. Network pharmacology prediction results suggested that the potential mechanisms of the four core medicinal herbs in SYS intervening H1N1 virus infection and subsequent lung injury was closely associated with the NLRP3 inflammasome-mediated pyroptosis pathway in the NOD-like receptor signaling pathway. Mechanistic studies demonstrated that SYS could suppress NF-κB activation, reduced the mRNA and protein expression of NLRP3, Caspase-1, and GSDMD, and inhibited Caspase-1 activation as well as the GSDMD protein cleavage mediated by activated Caspase-1.
      CONCLUSION SYS can ameliorate H1N1 virus-induced acute lung injury in mice by inhibiting the NF-κB-mediated NLRP3 inflammasome/pyroptosis pathway.

       

    /

    返回文章
    返回